Labcorp (LH) Q3 2026 Earnings Call Transcript

Labcorp reported Q3 2026 revenue of $3.81 billion, up 6.9%, adjusted EPS of $4.78, up 14.5%, and a 60-basis-point increase in adjusted operating margin to 15.0%; free cash flow rose to $412.2 million from $280.5 million. It raised 2026 adjusted EPS guidance to $18.30–$18.70 and revenue growth guidance to 5.9%–6.7%, citing underlying momentum, while reporting a $1.10 trailing 12-month biopharma book-to-bill. Management estimated proposed PAMA reimbursement changes could reduce 2027 revenue by about $125 million and said it expects to offset part of the impact; three acquisition agreements were announced after the quarter.

Analysis

Labcorp Holdings Inc. (LH): The stronger signal is not headline growth but operating leverage from organic diagnostic volume and central-lab demand. That supports earnings quality better than acquisition-led growth alone; however, higher study-start timing and working-capital-driven cash flow make extrapolation risky. The central-lab buildout adds upside if bookings convert, but creates utilization risk if pharma starts slip.

The key offset is reimbursement: the proposed PAMA reduction is a 2027 earnings headwind, not a direct one-for-one hit to revenue or profit. Its ultimate impact depends on the final schedule, payer spillover, contract repricing, and Labcorp’s ability to offset through productivity and mix. Smaller and regional labs may face greater pressure, potentially accelerating asset sales and improving LH’s acquisition pipeline—but also intensifying scrutiny of the economics and integration assumptions behind deals. Management’s accretion claims are not independently validated here. The Myriad Genetics (MYGN) asset sale could improve strategic focus, but its value to MYGN cannot be assessed without price, retained obligations, and revenue/profit contribution; avoid treating it as automatically bearish. Waters Corporation (WAT) collaboration appears strategically useful but is not yet a material earnings catalyst on supplied evidence.

Near term, execution and the raised outlook are supportive, but valuation and the immediate price reaction are unavailable, so avoid chasing. Over 1–3 months, track deal approvals/integration and central-lab bookings; over 6–18 months, PAMA implementation and offset delivery dominate. Contrarian risk: investors may over-credit acquisition synergies and treat working-capital cash-flow improvement as recurring. Thesis weakens if trailing book-to-bill falls below 1, organic volume decelerates, margins stop progressing, or final CMS rates exceed the assumed impact. Verify the filed release: the transcript contains apparent date and figure inconsistencies.

Key Decisions for Investors

• LH: Prefer a measured long on post-earnings weakness rather than chasing strength, conditional on valuation and the opening move; use February 2027 guidance as the next major test. Reassess if organic diagnostic volume or segment margins weaken.
• Keep BLS demand as a monitored catalyst, not a straight-line forecast: track trailing book-to-bill, backlog conversion, and study-start timing. A sustained book-to-bill below 1 or delayed conversions would challenge the growth thesis.
• Do not take a directional MYGN position from this asset-sale announcement alone. Verify consideration, retained costs/liabilities, and the prenatal business’s revenue and profit contribution before underwriting the effect.
• Treat the proposed PAMA schedule as a downside scenario until finalized. Monitor CMS actions, any RESULTS Act or delay, payer-contract spillover, and evidence that productivity savings offset the pressure.